Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological

US8999955B2 · kind B2 · utility

Assignee

• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Philippe Olivier Belmont · Val-de-Reuil, FR
• Laurent Meijer · Morlaix, FR
• Philip Cohen · Dundee, GB
• Amaury Patin · Lausanne, CH
• Johann Bosson · Gros-Morne, FR
• Peter Goekjian · Starkville, US

Key dates

• Filing date: Jan 19, 2009
• Grant date: Apr 7, 2015
• Expiry date: Oct 3, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/0812
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4═H; ether or polyether, amino; NO2; NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; N(R9,R10); —R5′═H or a C1-C12 alkyl, —R6═H; R; (R or R′)3—Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; —R7 and R8═H, C1-C12 alkyl; —R9 and R10═H, R (or R′) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.